Sandoz buys Aspen's Japanese generics business for up to $43...

Novartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to 400 million euros ($434 million).

FDA finally approves Sandoz's Neulasta biosimilar, but will ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta.

Sandoz says ‘no’ to Pear Therapeutics’ digital apps, handing...

Novartis strikes marketing deal for Polpharma's potential Ty...

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<

Three years after approval, court blocks US launch of Enbrel...

Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after appr

Optimising market access for biosimilars

We speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for biosimilars and what the future could hold for this still-bu